Profile data is unavailable for this security.
About the company
Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
- Revenue in JPY (TTM)311.30m
- Net income in JPY-975.80m
- Incorporated2015
- Employees28.00
- LocationNoile-Immune Biotech Inc6F, Ark Ginza Bldg., 7-17-2, GinzaMINATO-KU 105-0012JapanJPN
- Phone+81 358437819
- Websitehttps://www.noile-immune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA Chip Research Inc | 490.46m | -248.29m | 6.58bn | 36.00 | -- | 8.99 | -- | 13.43 | -39.09 | -39.09 | 77.17 | 108.27 | 0.5292 | 9.84 | 3.11 | -- | -26.79 | -23.49 | -32.60 | -26.70 | 13.53 | 14.28 | -50.62 | -54.10 | 2.92 | -2,206.97 | -- | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
| NIPPON CHEMIPHAR CO., LTD. | 30.75bn | -180.00m | 6.73bn | 872.00 | -- | 0.3089 | 5.76 | 0.219 | -49.89 | -49.89 | 8,520.20 | 5,115.78 | 0.6268 | 2.14 | 2.70 | -- | -0.3689 | 0.7482 | -0.5204 | 1.08 | 25.17 | 30.99 | -0.5887 | 1.13 | 1.53 | -- | 0.4791 | 50.33 | -2.57 | -2.10 | -153.10 | -- | 24.62 | -12.94 |
| Carna Biosciences, Inc. | 1.58bn | -1.03bn | 7.13bn | 67.00 | -- | 1.93 | -- | 4.51 | -60.32 | -60.32 | 92.24 | 205.19 | 0.3574 | 1.24 | 12.63 | 23,578,990.00 | -23.36 | -14.45 | -25.26 | -16.95 | 89.03 | 90.59 | -65.36 | -35.42 | 13.18 | -- | 0.0326 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
| Chiome Bioscience Inc | 642.70m | -1.30bn | 7.22bn | 51.00 | -- | 5.72 | -- | 11.23 | -25.56 | -25.56 | 12.60 | 22.39 | 0.3348 | 4.27 | 8.96 | 12,602,040.00 | -67.53 | -50.50 | -88.83 | -57.38 | 55.96 | 57.53 | -201.70 | -224.74 | 3.46 | -629.88 | 0.2009 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
| Veritas In Silico Inc | -100.00bn | -100.00bn | 7.22bn | 15.00 | -- | 3.06 | -- | -- | -- | -- | -- | 363.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 40.94 | -- | 0.00 | -- | 101.54 | -- | 123.38 | -- | -- | -- |
| MEDRx Co Ltd | 22.57m | -770.66m | 7.29bn | 22.00 | -- | 3.47 | -- | 323.20 | -20.97 | -20.97 | 0.6128 | 47.84 | 0.0143 | 0.00 | 4.22 | 1,025,955.00 | -48.80 | -58.15 | -50.27 | -62.23 | 100.00 | 95.70 | -3,414.38 | -1,526.17 | 43.57 | -- | 0.00 | -- | -50.35 | 28.60 | 16.04 | -- | -55.29 | -- |
| OncoTherapy Science, Inc. | 610.12m | -1.29bn | 7.41bn | 60.00 | -- | 18.46 | -- | 12.14 | -6.09 | -6.09 | 2.87 | 1.62 | 0.513 | 9.08 | 7.69 | -- | -108.31 | -55.67 | -182.73 | -63.82 | -29.13 | -1.49 | -211.13 | -247.47 | 2.07 | -189.93 | 0.232 | -- | -46.24 | 16.81 | -15.15 | -- | -48.33 | -- |
| Symbio Pharmaceuticals Ltd | 4.64bn | -2.74bn | 7.85bn | 109.00 | -- | 1.09 | -- | 1.69 | -66.88 | -66.88 | 113.80 | 156.38 | 0.5439 | 2.76 | 5.14 | 42,594,130.00 | -32.15 | -19.18 | -35.33 | -23.62 | 78.38 | 65.84 | -59.12 | -24.32 | 10.43 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Noile-Immune Biotech Inc | 311.30m | -975.80m | 8.01bn | 28.00 | -- | 1.50 | -- | 25.73 | -22.56 | -22.56 | 7.19 | 123.55 | 0.0658 | 0.139 | 5.07 | 11,118,000.00 | -20.62 | -- | -21.29 | -- | 99.55 | -- | -313.45 | -- | 52.74 | -805.65 | 0.00 | -- | -49.37 | -- | -192.28 | -- | -- | -- |
| CellSeed Inc | 193.68m | -892.21m | 8.24bn | 35.00 | -- | 3.83 | -- | 42.57 | -29.71 | -29.71 | 6.47 | 64.75 | 0.088 | 1.63 | 7.62 | 5,533,600.00 | -40.53 | -49.69 | -43.83 | -54.55 | 56.58 | 63.66 | -460.67 | -428.62 | 19.14 | -- | 0.0669 | -- | 50.39 | -28.62 | -11.43 | -- | 80.73 | -- |
| Kohjin Bio Co Ltd | 4.77bn | 384.98m | 8.81bn | 157.00 | 22.46 | 2.59 | 21.62 | 1.85 | 76.77 | 76.77 | 951.17 | 666.48 | -- | -- | -- | -- | -- | -- | -- | -- | 39.44 | -- | 8.07 | -- | 1.14 | -- | 0.4249 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| TMS Co Ltd | 0.00 | -960.04m | 8.83bn | 14.00 | -- | 2.55 | -- | -- | -25.89 | -25.89 | 0.00 | 85.77 | 0.00 | -- | -- | 0.00 | -26.14 | -- | -26.78 | -- | -- | -- | -- | -- | -- | -2,219.42 | 0.00 | -- | -- | -- | -11.51 | -- | -- | -- |
| CanBas Co Ltd (Parent) | 0.00 | -1.09bn | 8.99bn | 12.00 | -- | 3.00 | -- | -- | -64.47 | -64.47 | 0.00 | 166.10 | 0.00 | -- | -- | 0.00 | -43.91 | -65.86 | -45.99 | -79.11 | -- | -- | -- | -1,094.10 | -- | -- | 0.00 | -- | -- | -- | -45.41 | -- | -- | -- |
| Tsubota Laboratory Inc | 673.53m | -641.32m | 9.03bn | 10.00 | -- | 6.60 | -- | 13.41 | -25.15 | -25.15 | 26.42 | 53.45 | 0.2711 | 2.04 | 37.74 | -- | -25.82 | -- | -36.41 | -- | 3.17 | -- | -95.22 | -- | 2.31 | -489.86 | 0.0788 | -- | -29.45 | -- | -811.14 | -- | -- | -- |
| Wakamoto Pharmaceutical Co Ltd | 7.74bn | 108.96m | 9.16bn | 292.00 | 83.78 | 0.759 | 93.72 | 1.18 | 3.14 | 3.14 | 222.97 | 346.51 | 0.4971 | 2.09 | 2.57 | -- | 0.70 | -2.28 | 0.8046 | -2.64 | 46.52 | 51.00 | 1.41 | -3.97 | 3.85 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
| K Pharma Inc | 500.00m | -221.98m | 9.42bn | 15.00 | -- | 3.28 | -- | 18.85 | -18.94 | -18.94 | 43.04 | 247.43 | 0.2095 | 4.49 | -- | 33,333,330.00 | -9.30 | -- | -9.83 | -- | 91.00 | -- | -44.40 | -- | 42.60 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Noile-Immune Biotech Inc's reporting currency: Japanese Yen JPY
0.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 28 Jun 2023 | 130.10k | 0.30% |
| Simplex Asset Management Co., Ltd.as of 09 May 2024 | 48.70k | 0.11% |
| Federated Equity Management Company of Pennsylvaniaas of 31 Dec 2023 | 0.00 | 0.00% |
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
